Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 1/1b study titled ‘A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors.’ The study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-399, also known as Telisotuzumab vedotin, in patients with advanced solid tumors likely to express c-Met. This study is significant as it explores potential new treatments for challenging cancer types.
The intervention being tested is Telisotuzumab vedotin, an antibody-drug conjugate. It is administered in various dosing cycles, both as a monotherapy and in combination with other drugs such as osimertinib, erlotinib, and nivolumab. The purpose is to assess its effectiveness and safety in treating advanced solid tumors.
The study design is interventional with a non-randomized, sequential intervention model. There is no masking involved, meaning both researchers and participants know the treatment being administered. The primary purpose of the study is treatment-focused, aiming to find effective therapies for advanced solid tumors.
The study began on January 15, 2014, with the primary completion and estimated completion dates yet to be disclosed. The last update was submitted on August 11, 2025, indicating ongoing progress and adjustments in the study.
This clinical study update from AbbVie could influence the company’s stock performance and investor sentiment positively if the results show promise, especially in the competitive oncology market. Success in this study could position AbbVie favorably against competitors in the cancer treatment industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.